NYSE:ENZ - Enzo Biochem Stock Price, News & Analysis

-0.13 (-4.14 %)
(As of 08/26/2019 06:00 AM ET)
Today's Range
Now: $3.01
50-Day Range
MA: $3.63
52-Week Range
Now: $3.01
Volume255,146 shs
Average Volume137,177 shs
Market Capitalization$143.16 million
P/E RatioN/A
Dividend YieldN/A
Enzo Biochem, Inc, an integrated diagnostic bioscience company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates in three segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products segment manufactures, develops, and markets products and tools to clinical research, drug development, and bioscience research customers. Read More…

Industry, Sector and Symbol

Industry Medical laboratories



Sales & Book Value

Annual Sales$104.71 million
Book Value$1.72 per share


Net Income$-10,320,000.00


Market Cap$143.16 million
Next Earnings Date10/21/2019 (Estimated)

Receive ENZ News and Ratings via Email

Sign-up to receive the latest news and ratings for ENZ and its competitors with MarketBeat's FREE daily newsletter.

Enzo Biochem (NYSE:ENZ) Frequently Asked Questions

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its earnings results on Monday, June, 10th. The medical research company reported ($0.14) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.15) by $0.01. The medical research company earned $19.66 million during the quarter. Enzo Biochem had a net margin of 2.49% and a negative return on equity of 34.02%. View Enzo Biochem's Earnings History.

When is Enzo Biochem's next earnings date?

Enzo Biochem is scheduled to release their next quarterly earnings announcement on Monday, October 21st 2019. View Earnings Estimates for Enzo Biochem.

Has Enzo Biochem been receiving favorable news coverage?

News articles about ENZ stock have been trending positive on Monday, InfoTrie Sentiment Analysis reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Enzo Biochem earned a news sentiment score of 2.5 on InfoTrie's scale. They also assigned media stories about the medical research company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View News Stories for Enzo Biochem.

Are investors shorting Enzo Biochem?

Enzo Biochem saw a decrease in short interest during the month of July. As of July 31st, there was short interest totalling 812,300 shares, a decrease of 5.8% from the June 30th total of 862,100 shares. Based on an average daily trading volume, of 244,400 shares, the short-interest ratio is presently 3.3 days. Currently, 1.9% of the company's stock are sold short. View Enzo Biochem's Current Options Chain.

Who are some of Enzo Biochem's key competitors?

What other stocks do shareholders of Enzo Biochem own?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:
  • Dr. Elazar Rabbani, Co-Founder, Chairman, CEO & Sec. (Age 76)
  • Mr. Barry W. Weiner, Co-Founder, Pres, CFO, Principal Accounting Officer, Treasurer & Director (Age 69)
  • Mr. James Michael O'Brien, Exec. VP of Fin. (Age 53)
  • Dr. Dieter Schapfel, Chief Medical Director - Enzo Clinical Labs (Age 56)
  • Mr. Bruce A. Dey, VP of Sales & Marketing - Enzo Clinical Labs (Age 61)

Who are Enzo Biochem's major shareholders?

Enzo Biochem's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.76%), Renaissance Technologies LLC (6.84%), Vanguard Group Inc. (4.74%), Roumell Asset Management LLC (2.60%), Northern Trust Corp (1.18%) and Wells Fargo & Company MN (0.84%). Company insiders that own Enzo Biochem stock include Barry W Weiner, Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani, Gregory M Bortz, Harbert Management Corp and James Michael O'brien. View Institutional Ownership Trends for Enzo Biochem.

Which major investors are selling Enzo Biochem stock?

ENZ stock was sold by a variety of institutional investors in the last quarter, including Roumell Asset Management LLC, BlackRock Inc., Acadian Asset Management LLC, Marathon Capital Management, Los Angeles Capital Management & Equity Research Inc., Strs Ohio, Wells Fargo & Company MN and D. E. Shaw & Co. Inc.. View Insider Buying and Selling for Enzo Biochem.

Which major investors are buying Enzo Biochem stock?

ENZ stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Renaissance Technologies LLC, Susquehanna International Group LLP, Parametric Portfolio Associates LLC, Jane Street Group LLC, A.R.T. Advisors LLC, Citadel Advisors LLC and Bank of New York Mellon Corp. Company insiders that have bought Enzo Biochem stock in the last two years include Bruce A Hanna, Discovery Fund Lp Harbert, Elazar Rabbani and Harbert Management Corp. View Insider Buying and Selling for Enzo Biochem.

How do I buy shares of Enzo Biochem?

Shares of ENZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of ENZ stock can currently be purchased for approximately $3.01.

How big of a company is Enzo Biochem?

Enzo Biochem has a market capitalization of $143.16 million and generates $104.71 million in revenue each year. Enzo Biochem employs 460 workers across the globe.View Additional Information About Enzo Biochem.

What is Enzo Biochem's official website?

The official website for Enzo Biochem is http://www.enzo.com/.

How can I contact Enzo Biochem?

Enzo Biochem's mailing address is 527 Madison Ave., New York NY, 10022. The medical research company can be reached via phone at 212-583-0100.

MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  169 (Vote Underperform)
Total Votes:  332
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe ENZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ENZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/26/2019 by MarketBeat.com Staff

Featured Article: Catch-Up Contributions

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel